ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)

Trial Details

NCT ID
NCT06182072
Phase
PHASE1
Sponsor
ProDa BioTech, LLC
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • ProAgio Dose Levels (DL) 1,2,3,4
  • Gemcitabine, nab paclitaxel
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249

Key Eligibility Criteria

  • Must be ≥ 18 years of age on day of signing informed consent.
  • Histologic or cytologic diagnosis of pancreatic adenocarcinoma with clinical stage IV.
  • In the dose escalation phase: patients must be eligible for gemcitabine and nab paclitaxel. For dose expansion phase: patients must have received 5…
  • Presence of a lesion that can be safely biopsied for correlative assays.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →